HCV: ESPGHAN issues recommendations for pediatric treatment

Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • The European Society for Pediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) has issued a position paper regarding the treatment of pediatric HCV.

Why this matters

  • Ledipasvir/sofosbuvir (LDV/SOF) and sofosbuvir/ribavirin (SOF/RBV) are approved in the US/Europe for patients aged 12-17 years; peginterferon (PegIFN)+RBV  is used in younger children.

Study design

  • Systematic review/meta-analysis of studies involving PegIFN/RBV (11) or direct-acting antivirals (DAAs; 5).
  • ESPGHAN Hepatology Committee members voted on each recommendation.
  • Funding: None.

Recommendations

  • In the absence of high-risk factors, treatment can generally be deferred when PegIFN/RBV is the only option.
  • Interferon-free regimens are best for children aged >12 years weighing >35 kg; PegIFN/RBV is no longer recommended.
  • Children aged >12 years weighing >35 kg:
    • HCV-1/4: LDV/SOF for 12 weeks, extended to 24 weeks in treatment-experienced patients and those with compensated cirrhosis.
    • HCV-2: SOF plus weight-based RBV for 12 weeks.
    • HCV-3: SOF plus weight-based RBV for 24 weeks.
  • Children aged
  • PegIFN/RBV is no longer recommended as a general treatment.
  • Treatment initiation should be individualized based on HCV genotype, liver disease severity, adverse effects, likelihood of response, and comorbidities.
  • Experienced treatment center is recommended.
  • Possible off-label use of DAAs could be considered.

Limitations

  • Few DAA trials, all with very short follow-up.